Enfortumab vedotin + pembrolizumab (metastatic urothelial, 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ENFORTUMAB-VEDOTIN` `DRUG-PEMBROLIZUMAB`

ID	`REG-EV-PEMBRO-UROTHELIAL`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-EAU-BLADDER-2024` `SRC-NCCN-BLADDER-2025`

Notes

EV-302 paradigm 1L mUC. OS 31.5 vs 16.1 months.

Used By

Indication

IND-UROTHELIAL-METASTATIC-1L-EV-PEMBRO - IND-UROTHELIAL-METASTATIC-1L-EV-PEMBRO

Regimen

REG-EV-MONO-UROTHELIAL - Enfortumab vedotin monotherapy (urothelial carcinoma)